MCID: CHR073
MIFTS: 40

Choreatic Disease malady

Categories: Neuronal diseases, Blood diseases

Aliases & Classifications for Choreatic Disease

About this section

Aliases & Descriptions for Choreatic Disease:

Name: Choreatic Disease 11 13 68
Chorea 11 49 27 13 68
 
Hereditary Chorea 11 68

Classifications:



External Ids:

Disease Ontology11 DOID:12859
ICD1030 G25.5

Summaries for Choreatic Disease

About this section
Disease Ontology:11 A movement disease characterized by brief, semi-directed, irregular movements that not repetitive or rhythmic, but appear to flow from one muscle to the next.

MalaCards based summary: Choreatic Disease, also known as chorea, is related to choreoathetosis, hypothyroidism, and neonatal respiratory distress and chorea, hereditary benign, and has symptoms including rapid onset of sudden, jerky involuntary movements, head movements abnormal and oral choreiform movement. An important gene associated with Choreatic Disease is FRRS1L (Ferric Chelate Reductase 1 Like). Affiliated tissues include brain, testes and globus pallidus, and related mouse phenotypes are behavior/neurological and nervous system.

NINDS:49 Chorea is an abnormal involuntary movement disorder, one of a group of neurological disorders called

Related Diseases for Choreatic Disease

About this section

Diseases related to Choreatic Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 176)
idRelated DiseaseScoreTop Affiliating Genes
1choreoathetosis, hypothyroidism, and neonatal respiratory distress32.0ADCY5, NKX2-1
2chorea, hereditary benign12.4
3sydenham chorea12.3
4chorea gravidarum12.2
5huntington disease11.9
6chorea minor11.9
7morvan's fibrillary chorea11.9
8chorea and dementia11.9
9choreoacanthocytosis11.8
10chorea, remitting with nystagmus and cataracts11.8
11pontocerebellar hypoplasia, type 2e11.3
123-methylglutaconic aciduria, type iii11.0
13optic atrophy 3 with cataract10.9
14pontocerebellar hypoplasia type 2b10.8
15muscular dystrophy, limb-girdle, type 2e10.8
16myopathy with extrapyramidal signs10.8
17episodic kinesigenic dyskinesia 110.8
18pontocerebellar hypoplasia type 2a10.8
19neurodegeneration with brain iron accumulation 310.8
20pontocerebellar hypoplasia type 2c10.8
21dentatorubro-pallidoluysian atrophy10.7
22neuropathy, hereditary sensory and autonomic, type ii10.7
23basal ganglia calcification, idiopathic, 610.7
24dystonia, dopa-responsive, due to sepiapterin reductase deficiency10.7
25parkinsonism-dystonia, infantile10.7
26ataxia-telangiectasia10.7
27huntington disease-like 210.7
28sneddon syndrome10.7
29cerebellar ataxia and hypogonadotropic hypogonadism10.7
30rheumatic encephalitis10.7
31melanoma, cutaneous malignant, 510.4HTT, JPH3
32paroxysmal nonkinesigenic dyskinesia10.3PNKD, PRRT2
33atrial septal defect sinus venosus10.3NKX2-1, PRRT2
34rigidity and multifocal seizure syndrome, lethal neonatal10.2JPH3, TBP
35dystonia10.1
36neuronitis10.1
37okt4 epitope deficiency10.1HTT, JPH3, TBP
38interstitial keratitis10.1KEL, VPS13A
39corneal endothelial dystrophy 2, autosomal recessive10.1FTL, JPH3, VPS13A
40lupus erythematosus10.0
41rheumatic fever10.0
42syndromic x-linked intellectual disability type 1010.0
43dementia10.0
44cerebritis10.0
45systemic lupus erythematosus9.9
46moyamoya disease9.9
47encephalitis9.9
48encephalopathy9.9
49juvenile absence epilepsy9.9PNKD, PRRT2
50pandas9.9

Graphical network of the top 20 diseases related to Choreatic Disease:



Diseases related to choreatic disease

Symptoms & Phenotypes for Choreatic Disease

About this section

UMLS symptoms related to Choreatic Disease:


rapid onset of sudden, jerky involuntary movements, head movements abnormal, oral choreiform movement, involuntary movements, synkinesis, other symptoms involving nervous and musculoskeletal systems, hypokinesia, tremor, spasm, myoclonus, muscular fasciculation, dystonia, clonus, athetosis, ataxia

MGI Mouse Phenotypes related to Choreatic Disease according to GeneCards Suite gene sharing:

41
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053866.8ADCY5, FRRS1L, HTT, JPH3, KEL, NKX2-1
2MP:00036316.7HTT, JPH3, KEL, NKX2-1, PNKD, SGCE

Drugs & Therapeutics for Choreatic Disease

About this section

Drugs for Choreatic Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 158)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
DopamineapprovedPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 1375951-61-6, 62-31-7681
Synonyms:
(3H)-Dopamine
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-Dihydroxyphenyl)ethylamine
2-(3,4-dihydroxyphenyl)ethylamine
2-benzenediol
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3,4-dihydroxyphenethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)-Pyrocatechol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
4-(2-aminoethyl)-pyrocatechol
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
ASL 279
BIDD:ER0506
BPBio1_001123
BSPBio_001932
Biomol-NT_000001
C03758
CHEBI:18243
CHEMBL59
CID681
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine [INN:BAN]
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydroxytyramin
Hydroxytyramine
IDI1_000780
IP 498
Intropin
Intropin [*hydrochloride*]
KBio1_000780
 
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L-DOPAMINE
L000232
LDP
LS-159
Lopac-H-8502
Lopac0_000586
Medopa (TN)
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
SPECTRUM1505155
ST048774
STK301601
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
Spectrum_001012
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
cMAP_000036
cMAP_000065
dopamine
hydroxytyramine
intropin
m-Hydroxytyramine hydrochloride
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
2
Memantineapproved, investigationalPhase 4, Phase 217619982-08-24054
Synonyms:
1,3-Dimethyl-5-adamantanamine
1-Amino-3,5-dimethyladamantane
19982-08-2
3,5-Dimethyl-1-adamantanamine
3,5-Dimethyl-1-adamantylamine
3,5-Dimethyl-1-aminoadamantane
3,5-Dimethyladamantan-1-ylamine
3,5-Dimethyltricyclo(3.3.1.1(3,7))decan-1-amine
3,5-dimethyladamantan-1-amine
3,5-dimethyltricyclo[3.3.1.1~3,7~]decan-1-amine
41100-52-1 (Hydrochloride)
51052-62-1
AB00053600
AC1L1HB7
AKOS000113995
BBL000737
BPBio1_001117
BPBio1_001270
BSPBio_001015
Biomol-NT_000209
C13736
CBMicro_020348
CHEBI:152523
CHEMBL807
CID4054
D08174
DB01043
DMAA
DivK1c_000068
EU-0053634
Ebixa
Exiba
Exiba (TN)
HMS500D10
HSDB 7327
IDI1_000068
KBio1_000068
KBio2_001087
KBio2_003655
 
KBio2_006223
KBio3_001926
KBioGR_001543
KBioSS_001087
LS-157051
Lopac0_000861
Memantin
Memantina
Memantina [INN-Spanish]
Memantine
Memantine (INN)
Memantine HCL
Memantine Hydrochloride
Memantine [INN:BAN]
Memantine [INN]
Memantinum
Memantinum [INN-Latin]
MolPort-002-041-858
NCGC00015705-05
NCGC00024782-02
NCGC00024782-03
NINDS_000068
Namenda
Oprea1_480562
Prestwick0_000978
Prestwick1_000978
Prestwick2_000978
Prestwick3_000978
SPBio_001456
SPBio_002926
ST057652
STK520682
Spectrum2_001408
Spectrum3_000923
Spectrum4_001022
Spectrum5_001355
Spectrum_000607
UNII-W8O17SJF3T
ZERO/006024
memantine
3
LevodopaapprovedPhase 4, Phase 238859-92-76047
Synonyms:
(-)-(3,4-Dihydroxyphenyl)alanine
(-)-3-(3,4-Dihydroxyphenyl)-L-alanine
(-)-3-(3,4-dihydroxyphenyl)-L-alanine
(-)-Dopa
(2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate
(2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid
(−)-3-(3,4-dihydroxyphenyl)-L-alanine
(−)-dopa
.Beta.-(3, 4-Dihydroxyphenyl)alanine
.Beta.-(3,4-Dihydroxyphenyl)-L-alanine
1E83F927-C221-46AA-B90A-81B33C5F3868
2-Amino-3-(3,4-dihydroxyphenyl)propanoic acid
23734-74-9
25525-15-9
3, 4-Dihydroxy-L-phenylalanine
3, 4-Dihydroxyphenylalanine
3,4-DIHYDROXYPHENYLALANINE
3,4-Dihydroxy-L-phenylalanine
3,4-Dihydroxyphenyl-L-alanine
3,4-Dihydroxyphenylalanine
3,4-Dihydroxyphenylalanine (VAN)
3,4-dihydroxy-L-phenylalanine
3,4-dihydroxyphenylalanine
3-(3,4-Dihydroxypheny
3-(3,4-Dihydroxyphenyl)-L-alanine
3-Hydroxy-L-tyrosine
34241-25-3
37830_FLUKA
587-45-1
59-92-7
72572-99-7
72573-00-3
88250-23-1
90638-38-3
AC-11686
AC1L1LOR
AC1Q4U7F
BIDD:GT0158
BPBio1_000059
BSPBio_000053
BSPBio_002354
Bendopa
Bio-0575
Biodopa
Brocadopa
C00355
C9H11NO4
CAS-59-92-7
CCRIS 3766
CHEBI:15765
CHEMBL1009
CID6047
Cerepap
Cidandopa
D 9628
D00059
D0600
D9628
D9628_SIGMA
DAH
DB01235
DOPA
Deadopa
Dihydroxy-L-phenylalanine
Dihydroxyphenylalanine
DivK1c_000452
Dopa
Dopaflex
Dopaidan
Dopal
Dopal-Fher
Dopal-fher
Dopalina
Dopar
Dopar (TN)
Doparkine
Doparl
Dopasol
Dopaston
Dopaston SE
Dopastone
Dopastral
Dopicar
Doprin
EINECS 200-445-2
EU-0100454
Eldopal
Eldopar
Eldopatec
Eurodopa
HMS1568C15
HMS1922J14
HMS2090O08
HMS2093N04
HMS501G14
HSDB 3348
Helfo DOPA
 
Helfo-Dopa
Helfo-dopa
IDI1_000452
IV Levodopa
InChI=1/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14
Insulamina
KBio1_000452
KBio2_000934
KBio2_003502
KBio2_006070
KBioGR_001177
KBioSS_000934
L Dopa
L(-)-Dopa
L-(-)-Dopa
L-(3, 4-Dihydroxyphenyl)-.alpha.-alani
L-(3, 4-Dihydroxyphenyl)alanine
L-(o-Dihydroxyphenyl)alanine
L-.Beta.-(3,4-Dihydroxyphenyl)alanine
L-3,4-Dihydroxyphenylalanine
L-3,4-dihydroxyphenylalanine
L-3-(3,4-Dihydroxyphenyl)-Alanine
L-3-(3,4-Dihydroxyphenyl)alanine
L-3-Hydroxytyrosine
L-4-5-Dihydroxyphenylalanine
L-DOPA
L-DOPA, Parcopa, Atamet, Stalevo, Madopar, Prolopa, Dopar, 3,4-Dihydroxyphenylalanine, Levodopa
L-Dihydroxyphenylalanine
L-Dopa
L-O-Dihydroxyphenylalanine
L-b-(3,4-Dihydroxyphenyl)-a-alanine
L-beta-(3,4-Dihydroxyphenyl)-alpha-alanine
L-beta-(3,4-Dihydroxyphenyl)alanine
L-o-Hydroxytyrosine
LS-255
Laradopa
Larodopa
Ledopa
Levedopa
Levodopa
Levodopa (JP15/USP)
Levodopa (JP15/USP/INN)
Levodopa [USAN:INN:BAN:JAN]
Levodopum
Levodopum [INN-Latin]
Levopa
Lopac-D-9628
Lopac0_000454
MLS000028514
Maipedopa
MolPort-000-856-937
NCGC00015384-01
NCGC00016270-01
NCGC00016270-06
NCGC00093869-04
NINDS_000452
NSC 118381
NSC118381
PDSP1_001541
PDSP2_001525
Parda
Pardopa
Prestwick0_000017
Prestwick1_000017
Prestwick2_000017
Prestwick3_000017
Prestwick_185
Prodopa
Ro 4-6316
S1726_Selleck
SDCCGMLS-0066924.P001
SMR000058312
SPBio_000391
SPBio_001974
SPECTRUM2300205
Sobiodopa
Spectrum2_000496
Spectrum4_000539
Spectrum5_001899
Spectrum_000454
Syndopa
UNII-46627O600J
Veldopa
Weldopa
b-(3,4-Dihydroxyphenyl)-L-alanine
b-(3,4-Dihydroxyphenyl)-a-L-alanine
b-(3,4-Dihydroxyphenyl)alanine
beta-(3,4-Dihydroxyphenyl)-L-alanine
beta-(3,4-Dihydroxyphenyl)-alpha-L-alanine
beta-(3,4-Dihydroxyphenyl)-alpha-alanine
beta-(3,4-Dihydroxyphenyl)alanine
bmse000322
component of Sinemet
l)-L-alanine
nchembio.2007.55-comp26
nchembio.89-comp9
ne
β-(3,4-dihydroxyphenyl)alanine
4
TetrabenazineapprovedPhase 4, Phase 31658-46-86018
Synonyms:
1,2,4,6,7,11b-hexahydro-3-Isobutyl-9,10-dimethoxy-2H-benzo[a]quinolizin-2-one
1,3,4,6,7,11b-Hexahydro-3-isobutyl-9,10-dimethoxy-2H-benzo(a)quinolizin-2-one
1,3,4,6,7,11b-Hexahydro-3-isobutyl-9,10-dimethoxy-2H-benzo[a]quinolizin-2-one
1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-Benzo[a]quinolizin-2-one
2-Oxo-3-isobutyl-9,10-dimethoxy-1,2,3,4,6,7-hexahydro-11bH-benzo[a]quinolizine
2-Oxo-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11-beta-hexahydro-2H-benzoquinolizine
2-Oxo-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11.beta.-hexahydro-2H-benzoquinolizine
2-oxo-3-Isobutyl-9,10-dimethoxy-1,2,3,4,6,7-hexahydro-11bh-benzo[a]quinolizine
2-oxo-3-Isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-benzoquinolizine
2H-Benzo(a)quinolizin-2-one, 1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)- (9CI)
5-21-13-00178 (Beilstein Handbook Reference)
58-46-8
9,10-dimethoxy-3-(2-methylpropyl)-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one
9,10-dimethoxy-3-(2-methylpropyl)-1,3,4,6,7,11b-hexahydrobenzo[a]quinolizin-2-one
A2708/0115225
AC1L1LMF
AI3-52046
AKOS001681311
BRD-A47564106-001-01-8
BRN 0040090
C11168
CHEBI:293281
CHEMBL117785
CID6018
D08575
DB04844
EINECS 200-383-6
HMS1540E17
LS-40294
MLS001249426
MLS001249497
MLS003106727
MolPort-002-712-672
NCGC00160421-01
 
NCGC00160421-02
NSC 169886
NSC169886
NSC172187
Nitoman
Nitoman (TN)
Nitoman, Xenazine, Tetrabenazine
Oprea1_264344
Regulin
Ro 1-9569
Ro 1-9569/12
Rubigen
S1789_Selleck
SMR000718664
ST028814
STK678061
TBZ
TETRABENAZINE
TL8005032
Tetra benazin
Tetrabenazina
Tetrabenazina [INN-Spanish]
Tetrabenazina [inn-spanish]
Tetrabenazine (INN)
Tetrabenazine [INN:BAN]
Tetrabenazinum
Tetrabenazinum [INN-Latin]
Tetrabenazinum [inn-latin]
Tetrabenzaine
Tetrabenzine
TimTec1_002217
UNII-Z9O08YRN8O
WLN: T B666 DV GNTT&J E1Y1&1 LO1 MO1
Xenazine
Xenazine (TN)
tetra Benazin
5
AmantadineapprovedPhase 4, Phase 267768-94-52130
Synonyms:
1-Adamantamine
1-Adamantanamine
1-Adamantanamine (8CI)
1-Adamantylamine
1-Aminoadamantane
1-Aminotricyclo(3.3.1.1(sup 3,7))decane
1-adamantanamine
1-adamantylamine
1-aminoadamantane
138576_ALDRICH
665-66-7 (hydrochloride)
768-94-5
AB00514655
AC-11992
AC1L1CZI
AC1Q4UAF
AC1Q5396
ADAMANTANE,1-AMINO
AKOS000113994
AKOS000119324
Adamantamine
Adamantanamine
Adamantylamine
Amant
Amantadina
Amantadina [INN-Spanish]
Amantadine
Amantadine (INN)
Amantadine Base
Amantadine HCL
Amantadine Hydrochloride
Amantadine [INN:BAN]
Amantadinum
Amantadinum [INN-Latin]
Amantidine
Ambap768-94-5
Aminoadamantane
BIA4304
BIDD:GT0757
BPBio1_000368
BRN 2204333
BSPBio_000334
BSPBio_001570
BSPBio_001822
Bio-0821
C06818
C10H17N
CHEBI:2618
CHEMBL660
CID2130
D07441
DB00915
DivK1c_000815
EINECS 212-201-2
Endantadine
Gen-Amantadine
HMS1791O12
HMS1989O12
HSDB 3202
I14-1101
IDI1_000815
InChI=1/C10H17N/c11-10-4-7-1-8(5-10)3-9(2-7)6-10/h7-9H,1-6,11H
KBio1_000815
KBio2_000390
 
KBio2_002958
KBio2_005526
KBio3_001322
KBioGR_000548
KBioSS_000390
L000868
LS-157049
Lopac-A-1260
Lopac0_000004
Mantadine
MolPort-001-661-700
MolPort-001-760-587
MolPort-001-791-102
NCGC00015036-01
NCGC00015036-07
NCGC00162039-01
NCGC00162039-02
NCGC00162039-03
NCGC00162039-04
NCGC00179597-01
NCIOpen2_001059
NINDS_000815
NSC 341865
NSC341865
NSC83653
OR14310
Oprea1_248648
Pk-Merz
Pk-merz
Prestwick0_000407
Prestwick1_000407
Prestwick2_000407
Prestwick3_000407
SPBio_000002
SPBio_002273
STK298781
Spectrum2_000081
Spectrum3_000291
Spectrum4_000134
Spectrum5_000772
Spectrum_000030
Symadine
Symmetrel
TCMDC-125869
TL8005280
Tricyclo(3.3.1.1(3,7))-decan-1-amine
Tricyclo(3.3.1.1(sup 3,7))decan-1-amine
Tricyclo(3.3.1.1(sup 3.7))decan-1-amine
Tricyclo(3.3.1.13,7)decan-1-amine
Tricyclo[3.3.1.1(3,7)]decan-1-amine
Tricyclo[3.3.1.1(3,7)]decan-1-ylamine
Tricyclo[3.3.1.1(3,7)]decane-1-amine
Tricyclo[3.3.1.1(sup3,7)]decan-1-amine
Tricyclo[3.3.1.1^3,7]decan-1-amine
UNII-BF4C9Z1J53
Viregyt
Virosol
WLN: L66 B6 A B- C 1B ITJ BZ
Wiregyt
adamantan-1-amine
adamantan-1-ylamine
amantadine
amantadine hydrochloride
tricyclo[3.3.1.1(3,7)]decan-1-ylamine
tricyclo[3.3.1.1(3,7)]decane-1-amine
tricyclo[3.3.1.1~3,7~]decan-1-amine
6
CarbidopaapprovedPhase 417728860-95-934359, 38101
Synonyms:
(-)-L-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid
(-)-L-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid monohydrate
(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazino-2-methylpropanoic acid
(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid
(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid hydrate
(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid monohydrate
(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid--water (1/1)
(S)-(-)-carbidopa
(S)-(-)-carbidopa hydrate
(S)-(−)-carbidopa
(S)-alpha--Hydrazino-3,4-dihydroxy-alpha--methyl-benzenepropanoic acid monohydrate
(S)-carbidopa
(S)-carbidopa hydrate
(alphaS)-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid
(alphaS)-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid monohydrate
(αS)-α-hydrazino-3,4-dihydroxy-α-methylbenzenepropanoic acid
27925-91-3
28860-95-9
31823-41-3
38821-49-7
AC-1676
AC1L1RFR
AC1L1Z32
AC1Q5QGW
Atamet
BB_SC-5095
Benzenepropanoic acid, alpha-hydrazino-3,4-dihydroxy-alpha-methyl-, monohydrate, (S)
C-126
C-DOPA
C126_SIGMA
C1335_SIGMA
CCRIS 5093
CHEBI:3395
CHEBI:39585
CHEMBL1200748
CHEMBL1201236
CID34359
CID38101
CPD-11550
Carbidopa (anhydrous)
Carbidopa Anhydrous
Carbidopa Monohydrate
Carbidopa [USAN:INN:BAN]
Carbidopa anhydrous
Carbidopa hydrate
Carbidopa, (S)-Isomer
Carbidopa, Entacapone, & Levodopa
Carbidopa-1-wasser
 
Carbidopum
Carbidopum [INN-Latin]
DB00190
EINECS 249-271-9
EU-0100382
HMS2089B12
Hadrazino-alpha-methyldopa
Hydrocinnamic acid, (-)-L-alpha-hydrazino-3,4-dihydroxy-alpha-methyl-, monohydrate
KINSON, 3-(3,4-DIHYDROXY-PHENYL)-2-HYDRAZINO-2-METHYL-PROPIONIC ACID
L-3-(3,4-Dihydroxyphenyl)-2-methyl-2-hydrazinopropionic acid
L-3-(3,4-dihydroxyphenyl)-2-methyl-2-hydrazinopropionic acid
L-alpha-(3,4-dihydroxybenzyl)-alpha-hydrazinopropionic acid monohydrate
L-alpha-Methyl-alpha-hydrazino-beta-(3,4-dihydroxyphenylpropionic acid
L-alpha-Methyl-beta-(3,4-dihydroxyphenyl)-alpha-hydrazinopropionic acid
L-alpha-Methyldopahydrazine
L-α-methyldopahydrazine
LS-77199
Lodosin
Lodosyn
Lodosyn, Carbidopa
Lopac0_000382
MK 486
MK-485
MK-486
MLS000069628
MLS002207014
Methyldopahydrazine
MolPort-003-940-629
MolPort-005-934-181
N-Aminomethyldopa
NCGC00024596-01
NCGC00024596-03
NCGC00024596-05
NCGC00024596-06
S(-)-CARBIDOPA
S(-)-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid monohydrate
S-(-)-Carbidopa
S-(-)-alpha-Hydrazino-3,4-dihydroxy-2-methylbenzenepropanoic acid
S1891_Selleck
SMP1_000057
SMR000058235
ST055523
Stalevo
Tocris-0455
UNII-KR87B45RGH
UNII-MNX7R8C5VO
alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid
alpha-Methyldopahydrazine
carbidopa
carbidopum monohydricum
7Excitatory Amino AcidsPhase 4, Phase 3, Phase 2, Phase 11297
8Autonomic AgentsPhase 4, Phase 3, Phase 29774
9AnalgesicsPhase 4, Phase 3, Phase 2, Phase 111287
10Excitatory Amino Acid AntagonistsPhase 4, Phase 3, Phase 2, Phase 11282
11Antiparkinson AgentsPhase 4, Phase 21527
12DihydroxyphenylalaninePhase 4, Early Phase 1140
13Carbidopa, levodopa drug combinationPhase 4120
14Dopamine AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 13759
15Neurotransmitter AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 117734
16Protective AgentsPhase 4, Phase 3, Phase 2, Phase 17190
17Peripheral Nervous System AgentsPhase 4, Phase 3, Phase 2, Phase 122776
18Aromatic Amino Acid Decarboxylase InhibitorsPhase 4148
19Dopamine agonistsPhase 4618
20Adjuvants, ImmunologicPhase 42484
21Adrenergic AgentsPhase 4, Phase 3, Phase 2, Early Phase 15140
22Neurotransmitter Uptake InhibitorsPhase 4, Phase 3, Phase 23464
23Antiviral AgentsPhase 4, Phase 29732
24Analgesics, Non-NarcoticPhase 4, Phase 3, Phase 26260
25Anti-Infective AgentsPhase 4, Phase 2, Phase 3, Phase 121402
26
Cysteamineapproved, investigationalPhase 2, Phase 32760-23-16058
Synonyms:
(2-Mercaptoethyl)amine
(Mercaptoethyl)ammonium toluene-p-sulphonate
.beta.-Mercaptoethylamine
1-Amino-2-mercaptoethylamine
139720-70-0
156-57-0 (hydrochloride)
16904-32-8 (di-hydrochloride)
2-AMINO-ETHANETHIOL
2-AMINO-ethanethiol
2-Amino-1-ethanethiol
2-Aminoethanethiol
2-Aminoethyl mercaptan
2-Mercaptoethanamine
2-Mercaptoethylamine
2-Mercaptoethylamine, polymer-bound
27761-19-9 (tartrate (1:1))
2DFDA1F8-7010-4225-8280-AB1C4C43F546
30070_FLUKA
30070_SIGMA
3037-04-5
3037-04-5 (tosylate)
42954-15-4 (hydrobromide)
60-23-1
60-23-1 (Parent)
641022_ALDRICH
93965-19-6 (maleate (1:1))
A0648
AC1L1LPL
AC1Q54NL
AKOS003793343
Aminoethyl mercaptan
Becaptan
C-9500
C01678
C2H7NS
CASH
CCRIS 3083
CHEBI:17141
CHEMBL602
CID6058
CYSTEAMINE
Cisteamina
Cisteamina [Italian]
Cystavision
Cysteamide
Cysteamin
Cysteamine
Cysteamine (USAN)
Cysteamine [USAN:BAN]
Cysteamine bitartate
Cysteamine hydrochloride
Cysteaminium
Cysteinamine
D03634
DB00847
Decarboxycysteine
DivK1c_006750
 
EINECS 200-463-0
EINECS 221-235-7
Ethanethiolamine
HSDB 7353
KBio1_001694
KBio2_002235
KBio2_004803
KBio2_007371
KBioSS_002235
L 1573
L-1573
LS-65761
Lambraten
Lambratene
Lopac-M-6500
M9768_ALDRICH
M9768_SIGMA
MEA
MEA (mercaptan)
Mecramine
Mercamin
Mercamine
Mercaptamin
Mercaptamina
Mercaptamina [INN-Spanish]
Mercaptamine
Mercaptamine (INN)
Mercaptaminum
Mercaptaminum [INN-Latin]
Mercaptoethylamine
Merkamin
MolPort-001-662-635
NCGC00015691-01
NCGC00015691-04
NCGC00162236-01
NCI60_002000
NSC 647528
NSC647528
Riacon
STK315355
SpecPlus_000654
Spectrum_001755
Thioethanolamine
UNII-5UX2SD1KE2
WR 347
b-Aminoethanethiol
b-Aminoethylthiol
b-Mercaptoethylamine
beta-Aminoethanethiol
beta-Aminoethylthiol
beta-MEA
beta-Mercaptoethylamine
bmse000388
cysteamine bitartrate
nchembio.315-comp1
nchembio.316-comp1
β-MEA
β-aminoethylthiol
27
Riluzoleapproved, investigationalPhase 3631744-22-55070
Synonyms:
1744-22-5
2-Amino-6-(trifluoromethoxy)-benzothiazole
2-Amino-6-(trifluoromethoxy)benzothiazole
2-Amino-6-trifluoro- methoxybenzothiazole
2-amino-6-(trifluoromethoxy)-1,3-benzothiazole
2-amino-6-(trifluoromethoxy)benzo[d]thiazole
2-amino-6-(trifluoromethoxyl)benzothiazole
2-amino-6-trifluoromethoxybenzothiazole
6-(trifluoromethoxy)-1,3-benzothiazol-2-amine
6-(trifluoromethoxy)benzo[d]thiazol-2-amine
6-Trifluoromethoxy-benzothiazol-2-ylamine
6-trifluoromethoxybenzothiazole-2-yl-amine
AC-730
AC1L1JJL
AC1Q530H
AKOS000265071
ALBB-006046
Amino-2 trifluoromethoxy-6 benzothiazole
Amino-2 trifluoromethoxy-6 benzothiazole [French]
BB_SC-4839
BF-37
BIDD:GT0055
BPBio1_000037
BPBio1_000837
BRD-K21283037-001-02-5
BRD-K21283037-003-03-9
BSPBio_000033
Bio1_000416
Bio1_000905
Bio1_001394
Biomol-NT_000245
C07937
C8H5F3N2OS
CHEMBL744
CID5070
D00775
DB00740
EU-0101064
FT-0082997
HMS1773G08
HMS2089O19
HMS2094G07
I01-2084
LS-40688
 
Lopac-R-116
Lopac0_001064
MLS000069369
MolPort-000-151-262
NCGC00015882-01
NCGC00015882-02
NCGC00015882-03
NCGC00015882-07
NCGC00015882-11
NCGC00023141-02
NCGC00023141-04
NCGC00023141-05
NCGC00023141-06
PK-26124
PK-26124, RP-54274, Rilutek, Riluzole
Prestwick-03A08
Prestwick0_000167
Prestwick1_000167
Prestwick2_000167
Prestwick3_000167
R-116
R116_SIGMA
RP 54274
RP-54274
Rilutek
Rilutek (TN)
Riluzol
Riluzol [INN-Spanish]
Riluzole
Riluzole (JAN/USAN/INN)
Riluzole HCl
Riluzole [USAN:INN]
Riluzolum
Riluzolum [INN-Latin]
S1614_Selleck
SMR000058231
SPBio_000599
SPBio_001954
STK503686
Spectrum2_000550
Tocris-0768
UNII-7LJ087RS6F
ZERO/001785
ZINC00006481
riluzole
28
Minocyclineapproved, investigationalPhase 2, Phase 3, Phase 122410118-90-85281021
Synonyms:
(2Z,4S,4aS,5aR,12aS)-2-[amino(hydroxy)methylidene]-4,7-bis(dimethylamino)-10,11,12a-trihydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione
(4S,4AS,5AR,12AS)-4,7-BIS(DIMETHYLAMINO)-3,10,12,12A-TETRAHYDROXY-1,11-DIOXO-1,4,4A,5,5A,6,11,12A-OCTAHYDROTETRACENE-2-CARBOXAMIDE
(4S,4AS,5ar,12as)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
10118-90-8
13614-98-7 (mono-hydrochloride)
4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide
4708-96-7
7-Dimethylamino-6-demethyl-6-deoxytetracycline
AC1NQXWM
BRN 3077644
Bio-0062
Borymycin
C07225
C23H27N3O7
CHEBI:50694
CHEBI:529981
CHEMBL1434
CHEMBL259172
CID5281021
CL 59806
CRL-1605 & Minocycline
D05045
HMS2090D03
HSDB 3130
 
LMPK07000002
LS-93850
Lactoferrin B & Minocycline
Lactoferrin H & Minocycline
MINO
MIY
Minociclina
Minociclina [INN-Spanish]
Minociclinum
Minocin
Minocin (Hydrochloride)
Minocline
Minocyclin
Minocycline (USAN/INN)
Minocycline Monohydrochloride
Minocycline [USAN:BAN:INN]
Minocyclinum
Minocyclinum [INN-Latin]
NCGC00178854-01
NSC 141993
NSC141993
UNII-FYY3R43WGO
Vectrin (Hydrochloride)
minociclinum
minocycline
nchembio.559-comp1
29
Olanzapineapproved, investigationalPhase 3395132539-06-14585
Synonyms:
132539-06-1
2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno(2,3-b)(1,5)benzodiazepine
2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine
2-methyl-4-(4-methyl-1-piperazinyl)-10 H -thieno[2,3- b ] [1,5]benzodiazepine
2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine
2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]benzodiazepine
2-methyl-4-(4-methylpiperazin-1-yl)-5H-thieno[2,3-b][1,5]benzodiazepine
2-methyl-4-(4-methylpiperazin-1-yl)-5H-thieno[3,2-c][1,5]benzodiazepine
AC-665
AC1L1IHS
AKOS000282888
ALKS-7921
BIDD:GT0332
BIDD:PXR0138
Bio-0169
C07322
C076029
C17H20N4S
CHEBI:7735
CHEMBL715
CID4585
CPD000466345
D00454
DB00334
Eli Lilly brand of olanzapine
HMS2051H05
HMS2089M04
HMS2093I04
I06-0784
InChI=1/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H
InChI=1/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3
Jsp001969
KS-1090
L000455
L005958
LS-152313
LY 170053
LY-170052
 
LY-170053
Lanzac
Lilly brand of olanzapine
MLS000759457
MLS001165781
MLS001195646
MLS001424057
Midax
MolPort-002-885-845
MolPort-003-666-569
MolPort-005-977-341
NCGC00096077-01
NCGC00096077-03
NCGC00096077-04
Olansek
Olanzapin
Olanzapina
Olanzapine
Olanzapine (JAN/USAN/INN)
Olanzapine (OLA)
Olanzapine [USAN:INN]
Olanzapinum
S2493_Selleck
SAM001246652
SMR000466345
SPECTRUM1505024
STK634338
Symbyax
TL8000772
UNII-N7U69T4SZR
Zalasta
Zydis
Zyprexa
Zyprexa (TN)
Zyprexa Intramuscular
Zyprexa Velotab
Zyprexa Zydis
olanzapina
olanzapine
olanzapinum
30
Creatineapproved, nutraceuticalPhase 3, Phase 2, Phase 112657-00-1586
Synonyms:
((amino(Imino)methyl)(methyl)amino)acetic acid
((amino(imino)methyl)(methyl)amino)acetate
((amino(imino)methyl)(methyl)amino)acetic acid
(N-methylcarbamimidamido)acetic acid
(alpha-Methylguanido)acetate
(alpha-Methylguanido)acetic acid
(α-methylguanido)acetic acid
Cosmocair C 100
Creatin
Creatine
Creatine hydrate
Kreatin
 
Krebiozon
Methylglycocyamine
Methylguanidoacetate
Methylguanidoacetic acid
N-(Aminoiminomethyl)-N-Methyl-Glycine
N-(aminoiminomethyl)-N-methylglycine
N-Amidinosarcosine
N-Carbamimidoyl-N-methylglycine
N-Methyl-N-guanylglycine
N-[(e)-AMINO(imino)methyl]-N-methylglycine
Phosphagen
[[Amino(imino)methyl](methyl)amino]acetate
[[Amino(imino)methyl](methyl)amino]acetic acid
alpha-Methylguanidino acetic acid
31
Resveratrolexperimental, investigationalPhase 3112501-36-0, 955365-80-724856436, 445154
Synonyms:
(E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol
(E)-5-(p-Hydroxystyryl)resorcinol
(E)-5-[2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol
(E)-5-[2-(4-hydroxyphenyl)ethenyl]-1,3-benzendiol
(E)-resveratrol
 
3,4',5-Stilbenetriol
3,4',5-Trihydroxystilbene
3,4',5-trihydroxy-stilbene
MK-1775
trans-3,4',5 - Trihydroxystilbene
trans-3,4',5-trihydroxystilbene
trans-Resveratrol
32Gastrointestinal AgentsPhase 3, Phase 2, Phase 18109
33UbiquinonePhase 3, Phase 2, Phase 1139
34Central Nervous System DepressantsPhase 3, Phase 2, Phase 1, Early Phase 112806
35MicronutrientsPhase 3, Phase 2, Phase 15802
36Trace ElementsPhase 3, Phase 2, Phase 15802
37VitaminsPhase 3, Phase 25095
38Tranquilizing AgentsPhase 3, Phase 2, Phase 1, Early Phase 14164
39AntioxidantsPhase 3, Phase 22928
40Neuroprotective AgentsPhase 3, Phase 21672
41
SerotoninPhase 3, Phase 2356650-67-95202
Synonyms:
3-(2-Aminoethyl)-1H-indol-5-ol
3-(2-Aminoethyl)indol-5-ol
3-(b-Aminoethyl)-5-hydroxyindole
5-HT
5-HTA
5-Hydroxy-3-(b-aminoethyl)indole
 
5-Hydroxy-tryptamine
5-Hydroxyltryptamine
5-Hydroxytriptamine
5-Hydroxytryptamine
Antemovis
DS substance
Enteramin
Enteramine
42AntiemeticsPhase 33888
43AnticonvulsantsPhase 32620
44Anti-Bacterial AgentsPhase 2, Phase 3, Phase 110884
45Antipsychotic AgentsPhase 3, Early Phase 12359
46Dopamine AntagonistsPhase 3, Early Phase 11083
47Serotonin AgentsPhase 3, Phase 23102
48Psychotropic DrugsPhase 3, Phase 2, Phase 1, Early Phase 16279
49Serotonin Uptake InhibitorsPhase 3, Phase 21570
50Anti-Inflammatory Agents, Non-SteroidalPhase 34295

Interventional clinical trials:

(show top 50)    (show all 150)
idNameStatusNCT IDPhase
1Dopamine Treatment in Children With Cerebral Palsy With Dystonia- A Double Blind Controlled StudyUnknown statusNCT01361373Phase 4
2Study of Memantine to Treat Huntington's DiseaseUnknown statusNCT00652457Phase 4
3Impact of Xenazine(Tetrabenazine)on Gait and Functional Activity in Individuals With Huntington's DiseaseCompletedNCT01451463Phase 4
4Amantadine for Improving Neurologic Symptoms in Ataxia-TelangiectasiaCompletedNCT00950196Phase 4
5Different Dyskinesias in Parkinson's Disease and Their Relation to Levodopa PharmacokineticsCompletedNCT00888186Phase 4
6A Pilot Study Assessing Impulsivity in Patients With Huntington's Disease on Xenazine (Tetrabenazine)RecruitingNCT02509793Phase 4
7Effect of Tetrabenazine on Stroop Interference in HDRecruitingNCT01834911Phase 4
8Multicentric Trial of the Treatment of Huntington's Disease by Cysteamine (RP103)Unknown statusNCT02101957Phase 2, Phase 3
9First Time Use of SD-809 in Huntington DiseaseCompletedNCT01795859Phase 3
10Efficacy and Safety of Tetrabenazine in ChoreaCompletedNCT00219804Phase 3
11TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's DiseaseCompletedNCT00146211Phase 3
12A Safety and Efficacy Study of Dimebon in Patients With Huntington DiseaseCompletedNCT00920946Phase 3
13A Study of Pridopidine (ACR16) for the Treatment of Patients With Huntington's DiseaseCompletedNCT00724048Phase 2, Phase 3
14A Study of Treatment With Pridopidine (ACR16) in Patients With Huntington's DiseaseCompletedNCT00665223Phase 3
15Riluzole in Huntington's DiseaseCompletedNCT00277602Phase 3
16Pilot Study of Minocycline in Huntington's DiseaseCompletedNCT00277355Phase 2, Phase 3
17Family Health After Predictive Huntington Disease (HD) TestingCompletedNCT00075140Phase 3
18Neuroleptic and Huntington Disease Comparison of : Olanzapine, la Tetrabenazine and TiaprideRecruitingNCT00632645Phase 3
19WILSTIM - DBS (WILson STIMulation - Deep Brain Stimulation)RecruitingNCT02552628Phase 3
20Resveratrol and Huntington DiseaseRecruitingNCT02336633Phase 3
21Alternatives for Reducing Chorea in HDActive, not recruitingNCT01897896Phase 3
22An Extension of the HORIZON Protocol Evaluating the Safety of Dimebon (Latrepirdine) in Subjects With Huntington DiseaseTerminatedNCT01085266Phase 3
23Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E)TerminatedNCT00712426Phase 3
24Coenzyme Q10 in Huntington's Disease (HD)TerminatedNCT00608881Phase 3
25Safety and Efficacy of Bone Marrow Derived MNCs for Treatment of Cells for the Treatment of Hunting Tons Chorea.Unknown statusNCT01834053Phase 1, Phase 2
26Study in PRE-manifest Huntington's Disease of Coenzyme Q10 (UbiquinonE) Leading to Preventive Trials (PREQUEL)Unknown statusNCT00920699Phase 2
27MIG-HD: Multicentric Intracerebral Grafting in Huntington's DiseaseUnknown statusNCT00190450Phase 2
28Treatment of Huntington's Chorea With AmantadineCompletedNCT00001930Phase 2
29Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's DiseaseCompletedNCT02197130Phase 2
30Atomoxetine and Huntington's DiseaseCompletedNCT00368849Phase 2
31Citalopram to Enhance Cognition in HDCompletedNCT00271596Phase 2
32Famotidine for Levodopa-induced Dyskinesia in PDCompletedNCT01937078Phase 2
33Preventive Measures for Childhood-Onset Obsessive-Compulsive Disorder and Tic Disorders (PANDAS Subgroup)CompletedNCT00001359Phase 2
34Study Exploring Safety, Pharmacokinetic and Pharmacodynamic of BN82451 in Male Huntington's Disease PatientsCompletedNCT02231580Phase 2
35A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Versus Placebo for Symptomatic Treatment in Patients With Huntington's DiseaseCompletedNCT02006472Phase 2
36Apathy Cure Through Bupropion in Huntington's DiseaseCompletedNCT01914965Phase 2
37Proof of Concept of an Anaplerotic Study Using Brain Phosphorus Magnetic Resonance Spectroscopy in Huntington DiseaseCompletedNCT01882062Phase 2
38Study Evaluating The Safety, Tolerability And Brain Function Of 2 Doses Of PF-0254920 In Subjects With Early Huntington's DiseaseCompletedNCT01806896Phase 2
39Effect of PBT2 in Patients With Early to Mid Stage Huntington DiseaseCompletedNCT01590888Phase 2
40A Phase II Safety and Tolerability Study With SEN0014196CompletedNCT01521585Phase 2
41Neuroprotection by Cannabinoids in Huntington's DiseaseCompletedNCT01502046Phase 2
42A Trial of Memantine as Symptomatic Treatment for Early Huntington DiseaseCompletedNCT01458470Phase 2
43Creatine Safety & Tolerability in Huntington's DiseaseCompletedNCT01412151Phase 2
44Premanifest Huntington's Disease Extension Study II: Creatine Safety & TolerabilityCompletedNCT01411163Phase 2
45Premanifest Huntington's Disease: Creatine Safety & Tolerability Extension StudyCompletedNCT01411150Phase 2
46Effects of EGCG (Epigallocatechin Gallate) in Huntington's Disease (ETON-Study)CompletedNCT01357681Phase 2
47Creatine Safety and Tolerability in Premanifest HD: PRECRESTCompletedNCT00592995Phase 2
48A Study of the Novel Drug Dimebon in Patients With Huntington's DiseaseCompletedNCT00497159Phase 2
49Safety Study of the Novel Drug Dimebon to Treat Patients With Huntington's DiseaseCompletedNCT00387270Phase 1, Phase 2
50Safety and Tolerability Study of Phenylbutyrate in Huntington's Disease (PHEND-HD)CompletedNCT00212316Phase 2

Search NIH Clinical Center for Choreatic Disease

Genetic Tests for Choreatic Disease

About this section

Genetic tests related to Choreatic Disease:

id Genetic test Affiliating Genes
1 Chorea27

Anatomical Context for Choreatic Disease

About this section

MalaCards organs/tissues related to Choreatic Disease:

36
Brain, Testes, Globus pallidus, Skin, Skeletal muscle, Heart, Bone

Publications for Choreatic Disease

About this section

Variations for Choreatic Disease

About this section

Clinvar genetic disease variations for Choreatic Disease:

5
id Gene Variation Type Significance SNP ID Assembly Location
1FRRS1LNM_014334.2(FRRS1L): c.961C> T (p.Gln321Ter)SNVPathogenicrs878853280GRCh37Chr 9, 111899809: 111899809
2FRRS1LNM_014334.2(FRRS1L): c.845G> A (p.Trp282Ter)SNVPathogenicrs878853281GRCh38Chr 9, 109141360: 109141360
3FRRS1LNM_014334.2(FRRS1L): c.737_739delGAG (p.Gly246del)deletionPathogenicrs878853282GRCh38Chr 9, 109141466: 109141468
4FRRS1LNM_014334.3(FRRS1L): c.436dupA (p.Ile146Asnfs)duplicationPathogenicrs878853283GRCh38Chr 9, 109149676: 109149676

Expression for genes affiliated with Choreatic Disease

About this section
Search GEO for disease gene expression data for Choreatic Disease.

Pathways for genes affiliated with Choreatic Disease

About this section

GO Terms for genes affiliated with Choreatic Disease

About this section

Cellular components related to Choreatic Disease according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1dense core granuleGO:00310459.7SLC18A2, VPS13A

Biological processes related to Choreatic Disease according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1neuromuscular process controlling postureGO:00508849.9PNKD, PRRT2
2neuromuscular process controlling balanceGO:00508859.4ADCY5, GPR88, JPH3
3locomotory behaviorGO:00076268.9ADCY5, GPR88, NKX2-1, SLC18A2, VPS13A

Sources for Choreatic Disease

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet